This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
Signal Transduction and Targeted Therapy Open Access 27 April 2024
-
The IL-17 family in diseases: from bench to bedside
Signal Transduction and Targeted Therapy Open Access 11 October 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Ma, K. et al. IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. Cell. Mol. Immunol. https://doi.org/10.1038/s41423-020-00540-4 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clarke, J. IL-17 sustains plasma cells in SLE. Nat Rev Rheumatol 16, 666 (2020). https://doi.org/10.1038/s41584-020-00519-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-00519-5
This article is cited by
-
Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
Signal Transduction and Targeted Therapy (2024)
-
The IL-17 family in diseases: from bench to bedside
Signal Transduction and Targeted Therapy (2023)